Risk factors of severe COVID-19: a review of host, viral and environmental factors

L Zsichla, V Müller - Viruses, 2023‏ - mdpi.com
The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …

[HTML][HTML] Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance

M Leston, W Elson, JM Ordóñez-Mena, D Kar… - Journal of Infection, 2024‏ - Elsevier
Background Effective disease surveillance, including that for COVID-19, is compromised
without a standardised method for categorising the immunosuppressed as a clinical risk …

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort …

I Jyssum, H Kared, TT Tran, AT Tveter… - The Lancet …, 2022‏ - thelancet.com
Background In rituximab-treated patients with rheumatoid arthritis, humoral and cellular
immune responses after two or three doses of SARS-CoV-2 vaccines are not well …

Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial

CSR Araujo, AC Medeiros-Ribeiro, CGS Saad… - Annals of the rheumatic …, 2022‏ - Elsevier
Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate
(MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX …

Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study

G Figueroa-Parra, EL Gilbert… - The Lancet …, 2022‏ - thelancet.com
Background Rheumatoid arthritis has been associated with severe COVID-19, but few
studies have investigated how phenotypes of rheumatoid arthritis affect these associations …

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of …

A Sepriano, A Kerschbaumer, SA Bergstra… - Annals of the rheumatic …, 2023‏ - Elsevier
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 …

IFI44 is an immune evasion biomarker for SARS-CoV-2 and Staphylococcus aureus infection in patients with RA

Q Zheng, D Wang, R Lin, Q Lv, W Wang - Frontiers in immunology, 2022‏ - frontiersin.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a
global pandemic of severe coronavirus disease 2019 (COVID-19). Staphylococcus aureus is …

Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study

F Frost, D Nazareth, L Fauchier, D Wat… - European …, 2023‏ - publications.ersnet.org
Background Although people living with cystic fibrosis (PwCF) often have some risk factors
for cardiovascular disease, including diabetes and chronic inflammation, little is known …

Expert consensus: main risk factors for poor prognosis in COVID-19 and the implications for targeted measures against SARS-CoV-2

FJ Candel, P Barreiro, M Salavert, A Cabello… - Viruses, 2023‏ - mdpi.com
The clinical evolution of patients infected with the Severe Acute Respiratory Coronavirus
type 2 (SARS-CoV-2) depends on the complex interplay between viral and host factors. The …

Short term outcomes of COVID-19 in lupus: propensity score matched analysis from a nationwide multi-centric research network

R Raiker, H Pakhchanian, C DeYoung, L Gupta… - Journal of …, 2021‏ - Elsevier
Objectives To determine the severity and outcome of COVID-19 among individuals with
lupus as compared to controls. The secondary objective was to identify the risk association …